tailieunhanh - Rifabutin for treating pulmonary tuberculosis (Review)

Among current challenges in tuberculosis treatment are reducing the length of time that drugs must be taken to less than six months and finding ways to safely combine tuberculosis drugs with those used in the treatment of HIV infection. Rifabutin is a drug that has the potential to address these issues if substituted for rifampicin, a mainstay of current treatment. This review identified five trials involving 924 people, but none were of high quality. The review found no significant differences between rifabutin- and rifampicincontaining treatment in curing tuberculosis and preventing relapse, but higher doses of rifabutin might be associated with more adverse effects and there. | Rifabutin for treating pulmonary tuberculosis Review Davies GR Cerri S Richeldi L THE COCHRANE COLLABORATION This is a reprint of a Cochrane review prepared and maintained byThe Cochrane Collaboration and published in The Cochrane Library 2010 Issue 1 http WILEY J Publishers Since 1807 Rifabutin fortreating pulmonary tuberculosis Review Copyright 2010 The Cochrane Collaboration. Published by John Wiley Sons Ltd. TABLE OF CONTENTS HEADER . 1 ABSTRACT . 1 PLAIN LANGUAGE SUMMARY. 2 BACKGROUND. 2 OBJECTIVES . 3 METHODS. 3 RESULTS. 5 DISCUSSION. 7 AUTHORS CONCLUSIONS . 7 ACKNOWLEDGEMENTS . 8 REFERENCES. 8 CHARACTERISTICS OF STUDIES. 9 DATA AND ANALYSES. 14 Analysis . Comparison 1 Rifabutin vs rifampicin Outcome 1 Cure. 15 Analysis . Comparison 1 Rifabutin vs rifampicin Outcome 2 Relapse. 16 Analysis . Comparison 1 Rifabutin vs rifampicin Outcome 3 M. tuberculosis culture status 2 months after starting therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Analysis . Comparison 1 Rifabutin vs rifampicin Outcome 4 M. tuberculosis culture status 3 months after starting therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Analysis . Comparison 1 Rifabutin vs rifampicin Outcome 5 Adverse events. . . . . . . . . . . . . . 18 APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 WHAT S NEW. 20 HISTORY. 20 CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . . 21 INDEX TERMS . 21 Rifabutin for treating pulmonary tuberculosis Review Copyright 2010 The Cochrane Collaboration. Published by John Wiley Sons Ltd. i Intervention Review Rifabutin for treating pulmonary .